NVAX long after earningsI'm trying to learn my lesson here, it's ok to miss trades. There will always be more.
Going long at 160, not 180. After earnings, not before.
Will it work?
NVAX trade ideas
NVAX repriceDue to significant fundamental shift, the company seems to be cheap, judging by past data.
NVAX GAP TO FILL ABOVEAfter NVAX reported earnings last week it sold off in after hours, which left a big gap to fill upward from 202-226.
Vaccine stocks are ripping today, NVAX calls look good to fill the gap upward back to $226.
Once the gap is filled, if buyers are still in control then NVAX can test 227, 250.
NVAX fractal opportunity longNVAX fractal opportunity long. The logic is the same as Moderna fractal attached to this idea.
NET Swing ShortNET is a swing short. Targeting $111.11. Don't overstay you're welcome being short in NET. NET is definitely one of the next gen leaders of the stock market. It is still in an uptrend.
NVAX - Is it about to go up?According to Traders-Paradise Algorithm, this has a high chance of going up as the TakeProfit & StopLoss strategy indicate.
For day traders - 11/8/21: High chance for going up today.
NVAX GAP FILLEDGAP FILLED AND TARGET REACHED!!!
Closed my NVAX calls this morning and was up almost 300%, NVAX had a huge gap to fill after earnings sell off.
From here if NVAX holds it can test 263, 280 next.
Novavax break below of 175-225 range to retest demand at 130Novavax has tested its multi-decade supply area of 240-260 with no monthly closes above 260 since 2001.
Last week we tried to break out above the weekly range between 173 and 225 but failed.
Many bulls are now trapped in poor positions from 240.
My expectation is if we break below the gap down on the daily(186) and test last weeks low (177)and close near or below it, we will break below 175 for a test of 130.
cool technology but not so good managementNVAX has had a cool technology for a long time, but its management has not done a very good job in telling its story to the FDA (if a trader looks at its monthly chart).
Its Trend(obv) > zero along with a Bollinger Band squeeze on the top of the still-wide-opened Donchian Channel. So, it's about to rally!
Recount and more bleed to happenRecounted based on last week price action and looks like we have some more downside before we can kick start Wave 3.
Buy Novavax after earnings date?Novavax share price is at the point of the support zone. So maybe there is no difference when to buy a stock, now or after earnings date.
It is a matter of time before the vaccine is approved and share price will go higher.
P.S. I am not financial advisor, do your own search.
MARKET ALPHA VACCINE UPDATE - NVAXNASDAQ:NVAX
We got our pop higher on NVAX but we hit right into resistance. We still have bullish momentum trying to get through this level but if that weakens this could be another trap. This stock has the tendency to be extremely volatile so take your gains when you got them and don't stay in based off hopes and dreams.
I was wrong with my previous NVAX post! ill admit it :Dpreviously posted a short idea but it broke top trendline resistance! this went from bearish pattern to bullish now, look for a potential rally to 240 in short term, and then 300 after some consolidation. trend channel breakout patters are some of my favorite, these have a high probability of paying out :) good luck ! dont forget to like and follow if you enjoy my ideas <3
MARKET ALPHA WATCHLIST - NVAXNASDAQ:NVAX
For those that followed my post last week, we saw major gains in NVAX this week. This was expected as the delta variant information was being surpressed and the market had not totally digested it just yet. Now we are digesting the delta variant in a way that could be an over reaction but also may have some confluence with the fact the FED doesn't have much ammunition this time around in terms of interest rates.
Anyway, I expect NVAX to see higher levels but don't get caught chasing.
NVAX Novavax Analyst RatingsOn 6/15/2021 Cantor Fitzgerald brokerage Boosted the Price Target from Reduce to Overweight $217.00 to $272.00
On 5/18/2021 JPMorgan Chase & Co. brokerage Reiterated Rating from Overweight to Neutral $285.00 to $161.00
On 5/12/2021 B. Riley brokerage Lowered the Price Target from $365.00 to $286.00
On 5/12/2021 HC Wainwright brokerage Lowered the Price Target from $317.00 to $294.00
My personal price target is $240.
Looking forward to read your opinion.
NVAX long possibility 7/19NVAX is breaking out of the triangle and can be on its way right back up towards ATH.
Check out the chart
MARKET ALPHA WATCHLIST - NVAXSymbol: NASDAQ:NVAX
Indicators
Laguerre RSI
D-RSI
Multi-Time Frame EMA x2
Comments...
Delta Variant is rising and people are starting to get concerned. People will start to look at vaccine stocks at this may be an opportunity to find some reward.
Bearish side is that we are in a huge area of being rejected and the LaRSI may be indicating that could be true again.
Be careful on this one.
